A Prospective, Multinational, Multicenter, Randomized, Sequential, Double-blind, Placebo-controlled, Phase 2a Clinical Trial to Assess the Safety and Pharmacokinetics of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (ABC)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OMN-6 (Primary) ; Colistin; Meropenem
Indications Acinetobacter infections; Nosocomial pneumonia; Ventilator associated pneumonia
Focus Adverse reactions; Pharmacokinetics
Sponsors Omnix Medical

Most Recent Events

26 Feb 2025 Planned initiation date (estimated date of first participant enrollment) changed from 1 Jan 2025 to 1 Feb 2025.
31 Dec 2024 Planned initiation date changed from 9 Oct 2024 to 1 Jan 2025.
14 Oct 2024 Planned initiation date changed from 16 Sep 2024 to 9 Oct 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight